PTC Therapeutics, Inc (PTCT) saw its loss narrow to $29.06 million, or $0.85 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $41.23 million, or $1.22 a share. Revenue during the quarter surged 40.50 percent to $26.55 million from $18.90 million in the previous year period.
Operating loss for the quarter was $26.36 million, compared with an operating loss of $38.44 million in the previous year period.
“We are thrilled to bring EMFLAZA to Duchenne muscular dystrophy patients in the United States,” said Stuart W. Peltz, Ph.D., chief executive officer, PTC Therapeutics, Inc. “The acquisition of EMFLAZA supports our commitment to providing new treatment options for Duchenne patients. We plan to launch EMFLAZA in the coming weeks and are focused on providing access to all eligible patients. We are also pleased with Translarna’s continued sales growth outside the U.S. with another strong quarter. With Translarna and EMFLAZA, we now have two of the three approved Duchenne drugs globally.”
Ptc Therapeutics forecasts revenue to be in the range of $115 million to $130 million for fiscal year 2017.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
